Untitled 1
[TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY,
PART II, SECTION 3,
SUB-SECTION (i)]
GOVERNMENT OF INDIA
MINISTRY OF FINANCE
(Department of Revenue)
Notification No. 09/2025-Customs
New Delhi, the 1st February, 2025
G.S.R….(E).- In exercise of the powers conferred by sub-section (1) of
section 25 of the Customs Act,
1962 (52 of 1962), the Central Government, on being satisfied that it is
necessary in the public interest so to do,
hereby makes the following further amendments in the notification of the
Government of India in the Ministry of
Finance (Department of Revenue) No. 16/2017-Customs, dated the 20th April, 2017,
published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R.
394(E), dated the 20th April, 2017,
namely :-
In the said notification, in the TABLE, after serial number 52 and the
entries relating thereto, the following
serial numbers and the entries shall be inserted, namely :-
(1) |
(2) |
(3) |
(4) |
“53. |
Pembrolizumab |
Key- PAP 1.0 MSD |
Pharmaceuticals |
54. |
Pembrolizumab KIRAN MSD |
KIRAN MSD |
Pharmaceuticals |
55 |
Lorlatinib LorbriquaCare |
LorbriquaCare |
Pfizer Products India Private Ltd. |
56 |
Dacomitinib |
DacoCare Pfizer |
Products India Private Ltd. |
57 |
Inotuzumab Ozogamicin |
HemaCare Pfizer |
Products India Private Ltd |
58 |
Ribociclib |
UMAANG |
Novartis Healthcare Pvt. Ltd. |
59 |
Dabrafenib |
UMAANG |
Novartis Healthcare Pvt. Ltd. |
60 |
Selumetinib |
AstraZeneca Pharma |
AstraZeneca Pharma India Limited |
61 |
Benralizumab |
AstraZeneca Pharma PAP |
AstraZeneca Pharma India Limited |
62 |
Fulvestrant |
AstraZeneca Pharma |
AstraZeneca Pharma India Limited |
63 |
Acalabrutinib |
AstraZeneca Pharma PAP |
AstraZeneca Pharma India Limited |
64 |
Olaparib |
AstraZeneca Pharma PAP |
AstraZeneca Pharma India Limited |
65 |
Amivantamab |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
66 |
Teclistamab |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
67 |
Ustekinumab |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
68 |
Daratumumab
And hyaluronidase-fihj |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
69 |
Ibrutinib |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
70 |
Bortezomib |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
71 |
Daratumumab |
Johnson and Johnson PAP |
Johnson & Johnson Pvt. Ltd. |
72 |
Cetuximab |
Rainbow PAP |
Merck Specialties Pvt. Ltd. |
73 |
Avelumab |
My Bavencio Assist Program |
Merck Specialties Pvt. Ltd. |
74 |
Tepotinib |
My Tepmetko Patient Access
Program |
Merck Specialties Pvt. Ltd. |
75 |
Brentuximab Vedotin |
Takeda PAP |
Biopharmaceuticals India Pvt.
Limited |
76 |
Vedolizumab |
Takeda PAP |
Takeda Biopharmaceuticals India Pvt.
Limited |
77 |
Velaglucerase |
Takeda PAP |
Takeda Biopharmaceuticals India Pvt.
Limited |
78 |
Agalsidase Alpha |
Takeda PAP |
Biopharmaceuticals India Pvt.
Limited |
79 |
Idursulphase |
Takeda PAP |
Takeda Biopharmaceuticals India Pvt.
Limited |
80 |
Mepolizumab |
GSK Pharmaceuticals Limited |
GSK Pharmaceuticals Limited |
81 |
Alectinib |
The Blue Tree |
Roche Products India Private Ltd. |
82 |
Risdiplam Powder |
The Blue Tree |
Roche Products India Private Ltd. |
83 |
Emicizumab |
The Blue Tree |
Roche Products India Private Ltd. |
84 |
Atezolizumab |
The Blue Tree |
Products India Private Ltd. |
85 |
Pertuzumab +
trastuzumab |
The Blue Tree |
Products India Private Ltd. |
86 |
Ocrelizumab |
The Blue Tree |
Roche Products India Private Ltd. |
87 |
Polatuzumab vedotin |
The Blue Tree |
Roche Products India Private Ltd. |
88 |
Faricimab |
The Blue Tree |
Roche Products India Private Ltd |
89 |
Luspatercept |
Bristol-Myers Patient Assistance
Program |
Bristol-Myers Squibb India Pvt. Ltd. ” |
2. This notification shall come into force on the 2nd day of February, 2025.
[F. No. 334/03/2025-TRU]
(Amreeta Titus)
Deputy Secretary to the Government of India
Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017
was published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-Section (i), vide number G.S.R.
394(E), dated the 30th June, 2017.
|